RTI Biologics Announces 2012 Third Quarter Results

RTI Biologics Announces 2012 Third Quarter Results

Company Will Hold Conference Call at 8:30 a.m. ET

ALACHUA, Fla.--(BUSINESS WIRE)-- RTI Biologics Inc. (RTI) (NAS: RTIX) , a leading provider of orthopedic and other biologic implants, reported operating results for the third quarter of 2012 as follows:


Quarterly Highlights:

  • Achieved quarterly revenues of $44.6 million, a 5 percent increase over the third quarter of 2011.

  • Achieved quarterly net income per fully diluted share of $0.05.

  • Achieved quarterly revenues of $11.8 million in the sports medicine business, a 7 percent increase over the third quarter of 2011.

  • Achieved quarterly revenues of $7.9 million in the surgical specialties business, a 5 percent increase over the third quarter of 2011.

  • Achieved quarterly revenues of $7.9 million in the bone graft substitutes and general orthopedic (BGS/GO) business, a 13 percent increase over the third quarter of 2011.

  • Achieved quarterly revenues of $5.2 million in the dental business, a 15 percent increase over the third quarter of 2011.

  • Achieved quarterly revenues of $12.8 million in the U.S. direct distribution organization, a 5 percent increase over the third quarter of 2011. The U.S. direct distribution organization includes sports medicine and certain BGS/GO implants.

"Revenues in the third quarter met expectations and were driven primarily by continued growth in our dental, BGS/GO, direct sports medicine and surgical specialties businesses," said Brian K. Hutchison, president and chief executive officer of RTI.

Worldwide revenues of $44.6 million for the third quarter of 2012 increased 5 percent compared to the third quarter of 2011. Domestic revenues of $39.6 million for the third quarter of 2012 grew by 6 percent compared to the third quarter of 2011, primarily based on the strength of the dental, BGS/GO, surgical specialties and direct sports medicine businesses and were offset by continued weakness in the spine business. International revenues of $4.9 million for the third quarter of 2012 declined slightly as compared to the third quarter of 2011. On a constant currency basis, international revenues increased 9 percent as compared to the third quarter of 2011 due to higher distributions of BGS/GO.

For the third quarter of 2012, the company reported net income of $2.8 million and net income per fully diluted share of $0.05, based on 56.1 million fully diluted shares outstanding, compared to net income of $2.7 million or $0.05 per fully diluted share for the third quarter of 2011, based on 55.4 million fully diluted shares outstanding. Net income per fully diluted share for the third quarter of 2011 was favorably impacted by approximately $0.01 due to the de-recognition of an uncertain tax liability as a result of Internal Revenue Service guidance provided during the third quarter of 2011 and applicable to the deductibility of transaction fees incurred as part of the Tutogen merger in 2008.

FDA Warning Letter

On Oct. 23, 2012 the company received a warning letter from the FDA related to environmental monitoring activities in certain areas of its Alachua, Fla. processing facility. The company is committed to actively working with the FDA to address their concerns. The warning letter does not restrict the company's ability to process or distribute implants, nor does it require the withdrawal of any implants from the marketplace. The issuance of the warning letter has no impact on patient safety.

"We pride ourselves on operating in the right way, and are dedicated to providing high quality, safe biologic implants to surgeons and their patients," Hutchison said. "While this issue has no impact on patient safety, we take this matter very seriously, and are committed to fully resolve any issues."

Fiscal 2012 and Fourth Quarter Outlook

Based on results through the first three quarters, the company is narrowing its full year revenue guidance for 2012. The company expects full year revenues for 2012 to be between $178 million and $179 million.

The company expects full year net income per fully diluted share for 2012 to be approximately $0.15, based on 56.1 million shares outstanding. Excluding a pre-tax litigation settlement charge of $2.35 million taken in the second quarter of 2012, or $0.03 per fully diluted share, the company expects full year net income per fully diluted share for 2012 to be approximately $0.18, based on 56.1 million shares outstanding.

For the fourth quarter of 2012, the company expects revenues to be between $44 million and $45 million, and net income per fully diluted share to be $0.04.

"With solid results for the third quarter of 2012, we remain on track to meet our financial goals for the year," Hutchison said.

Conference Call

RTI will host a conference call and simultaneous audio webcast to discuss the third quarter results at 8:30 a.m. ET today. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI's website at www.rtix.com. A replay of the conference call will be available on the RTI website following the call.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and animal tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI's innovations continuously raise the bar of science and safety for biologics - from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. The BioCleanse® Tissue Sterilization Process, the Tutoplast® Tissue Sterilization Process and the Cancelle™ SP Demineralization Processhave a combined record of more than four million implants distributed with zero incidence of implant-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI's worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's website at www.rtix.com or the SEC's website at www.sec.gov.

RTI BIOLOGICS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2012

2011

2012

2011

Revenues:

Tissue distribution

$ 43,034

$ 40,490

$ 128,866

$ 121,513

Other revenues

1,532

1,767

4,640

4,872

Total revenues

44,566

42,257

133,506

126,385

Costs of processing and distribution

22,874

22,934

70,037

69,006

Gross profit

21,692

19,323

63,469

57,379

Expenses:

Marketing, general and administrative

14,499

13,664

43,167

41,759

Research and development

3,109

2,510

9,279

7,407

Asset abandonments

-

1

18

58

Litigation settlement

-

-

2,350

-

Total operating expenses

17,608

16,175

54,814

49,224

Operating income

4,084

3,148

8,655

8,155

Total other income (expense) - net

32

(29)

138

(168)

Income before income tax provision

4,116

3,119

8,793

7,987

Income tax provision

(1,308)

(377)

(2,662)

(1,979)

Net income

$ 2,808

$ 2,742

$ 6,131

$ 6,008

Net income per common share - basic

$ 0.05

$ 0.05

$ 0.11

$ 0.11

Net income per common share - diluted

$ 0.05

$ 0.05

$ 0.11

$ 0.11

Weighted average shares outstanding - basic

55,908,574

55,167,178

55,826,306

55,071,761

Weighted average shares outstanding - diluted

56,110,898

55,397,794

56,013,541

55,205,997

RTI BIOLOGICS, INC. AND SUBSIDIARIES

Reconciliation of Net Income and Net Income Per Diluted Share to

Adjusted Net Income and Adjusted Net Income Per Diluted Share

(In thousands except per share data)

(Unaudited)

Nine Months Ended

September 30, 2012

September 30, 2011

Amount

Amount

Net

per Diluted

Net

per Diluted

Income

Share

Income

Share

As reported

$

6,131

$

0.11

$

6,008

$

0.11

Litigation settlement charge,

net of tax effect (1)

1,444

0.03

-

-

Adjusted

$

7,575

$

0.14

$

6,008

$

0.11

(1) Litigation settlement charge, net of tax effect, as follows:

Litigation settlement charge

$

2,350

Tax effect on litigation settlement charge

(906

)

Litigation settlement charge, net of tax effect

$

1,444

Use of Non-GAAP Financial Measures

To supplement RTI Biologic's condensed consolidated financial statements presented on a GAAP basis, the company discloses certain non-GAAP financial measures that exclude certain amounts, including non-GAAP net income and non-GAAP net income per fully diluted share. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP measures are included in the reconciliation above.

The following is an explanation of the adjustment that management excluded as part of the non-GAAP measures for the nine month period ended September 30, 2012 as well as the reasons for excluding the individual item:

Litigation settlement - This adjustment represents a charge and relates to a litigation settlement of certain BTS related lawsuits. Management removes the amount of the litigation settlement charge from the Company's operating results to assist in assessing its operating performance in the year-to-date period and to supplement a comparison to the Company's past operating performance.

Material Limitations Associated with the Use of Non-GAAP Financial Measures

Non-GAAP net income and non-GAAP net income per fully diluted share should not be considered in isolation, or as a replacement for GAAP measures.

Usefulness of Non-GAAP Financial Measures to Investors

The Company believes that presenting non-GAAP net income and non-GAAP net income per fully diluted share in addition to the related GAAP measures provide investors greater transparency to the information used by management in its financial decision-making which excludes the litigation settlement charge. The Company further believes that providing this information better enables RTI Biologic's investors to understand the Company's overall core performance and to evaluate the methodology used by management to assess and measure such performance.

RTI BIOLOGICS, INC. AND SUBSIDIARIES

Condensed Consolidated Revenues

(In thousands)

(Unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2012

2011

2012

2011

Revenues from tissue distribution:

Sports medicine

$

11,811

$

11,072

$

38,573

$

34,881

Spine

10,187

10,322

28,532

31,060

Surgical specialties

7,880

7,519

24,136

22,583

Bone graft substitutes and general orthopedic

7,916

7,026

21,947

19,374

Dental

5,240

4,551

15,678

13,615

Other revenues

1,532

1,767

4,640

4,872

Total revenues

$

44,566

$

42,257

$

133,506

$

126,385

Domestic revenues

39,643

37,282

116,707

110,507

International revenues

4,923

4,975

16,799

15,878

Total revenues

$

44,566

$

42,257

$

133,506

$

126,385

RTI BIOLOGICS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

September 30,

December 31,

2012

2011

Assets

Cash and cash equivalents

$

55,242

$

46,178

Accounts receivable - net

20,742

20,674

Inventories - net

72,316

76,598

Prepaid and other current assets

16,887

16,231

Total current assets

165,187

159,681

Property, plant and equipment - net

46,613

44,532

Other assets - net

24,257

25,814

Total assets

$

236,057

$

230,027

Liabilities and Stockholders' Equity

Accounts payable

$

9,790

$

11,141

Accrued expenses and other current liabilities

24,474

24,028

Current portion of long-term obligations

185

448

Total current liabilities

34,449

35,617

Deferred revenue

19,995

20,589

Long-term liabilities

1,082

1,402

Total liabilities

55,526

57,608

Stockholders' equity:

Common stock and additional paid-in capital

413,882

411,741

Accumulated other comprehensive loss

(2,344

)

(2,184

)

Accumulated deficit

(231,007

)

(237,138

)

Total stockholders' equity

180,531

172,419

Total liabilities and stockholders' equity

$

236,057

$

230,027

RTI BIOLOGICS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

Three Months Ended

Nine Months Ended